Retatrutide Side Effects: Phase 2 Trial Data & Management

Most Common Side Effects

In the Phase 2 SURMOUNT trial (NCT05019001), the most frequently reported adverse events were gastrointestinal in nature and consistent with other GLP-1 class peptides. Rates were dose-dependent, occurring more frequently in the 12 mg arm than in the 4 mg or 8 mg arms.

Why GI Effects Are More Pronounced than Semaglutide

Retatrutide activates three receptors simultaneously: GLP-1R, GIPR, and GCGR (glucagon). The glucagon receptor component, absent in semaglutide and tirzepatide, contributes to accelerated gastric emptying — which amplifies nausea particularly in the first 4–8 weeks. However, the same glucagon activity also enhances fat oxidation, which contributes to the superior weight loss outcomes.

Cardiovascular and Metabolic Changes

Phase 2 data showed a modest increase in mean heart rate of approximately 2–4 bpm across all dose arms — consistent with GLP-1 class effects. Importantly, blood pressure decreased significantly: systolic BP dropped an average of 6–8 mmHg in the 8 mg and 12 mg arms, and triglycerides reduced by approximately 30% at 24 weeks.

No major adverse cardiovascular events (MACE) attributable to the compound were reported in Phase 2. Phase 3 TRIUMPH cardiovascular outcomes trials are ongoing.

Discontinuation Rates

Treatment discontinuation due to adverse events was reported at 7% in the 4 mg arm, 9% in the 8 mg arm, and 16% in the 12 mg arm at 48 weeks. Nearly all discontinuations were GI-related and occurred during the first 12 weeks of titration — supporting the value of a slow titration schedule.

Minimising Side Effects Through Titration

The most effective strategy for reducing GI side effects is a graduated titration schedule starting at 2 mg weekly. Research protocols that begin at 4 mg or higher without a 2–4 week 2 mg initiation phase report significantly higher rates of early dropout due to nausea.

Additional management strategies observed in research contexts include: administering injections in the evening, reducing meal size on injection day, avoiding high-fat meals in the 6 hours following injection, and staying well-hydrated.

Injection Site Reactions

Mild injection site reactions (redness, mild swelling, bruising) were reported in approximately 7–10% of participants across all arms. These are consistent with subcutaneous injection of any lyophilized peptide and are generally self-limiting within 24–48 hours. Rotating injection sites (abdomen, thigh, upper arm) reduces the frequency of these reactions.